Tonix Pharmaceuticals Holding Corp. - 8-K Filing
Tonix Pharmaceuticals receives FDA alignment on adaptive Phase 2 field study design for TNX-4800 to prevent Lyme disease in adults. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $TNXP